Search Thermo Fisher Scientific
Search Thermo Fisher Scientific
Pharmacogenomics, the understanding of how genes impact an individual's response to medications, plays an important role in certain prescribing situations through the identification of medication responders and non-responders. The utilization of pharmacogenomics assists in optimizing drug dose and avoiding adverse events, including toxicity and even death.
Using microarray analysis across predictive genomics applications, such as pre-emptive pharmacogenomics research areas, helps garner greater insights. This means researchers and scientists can be better informed and can confidently make decisions that support precision medicine efforts.
Significant progress has been made using genomics to help determine the safest, most effective course of treatments for individuals. As these programs scale and go mainstream, they are beginning to deliver on the promise of helping improve the health of communities and lowering healthcare costs.
As one example, the Teachers' Retirement System of Kentucky recently launched a pilot program that is already showing positive results from both an individual impact and cost-savings perspective. First, members who opt in receive a saliva collection kit which is analyzed using one of Thermo Fisher Scientific's pharmacogenomics technologies. Next, pharmacists review the participant's genetic results—along with health data such as drug, lifestyle, and food interactions—to customize a “Medication Action Plan” that members' physicians can access to determine which drugs should be changed to help increase safety and efficacy.
Thermo Fisher Scientific's predictive genomics solutions are part of an efficient workflow and can be scaled to your testing needs. We provide input on what is needed to customize your array, with hands-on support from start to finish so you can remain focused on shaping the future of healthcare.
Population genotyping projects are enabling precision medicine decisions and helping improve health care outcomes. Many national governments and large organizations are investing in scaling up genotyping infrastructure to enable personalized solutions.
Our Axiom solution consists of a technology platform that includes assay biochemistry, automated and manual target preparation options, multiple array plate formats, and array processing on the GeneTitan Multi-Channel Instrument. This solution has applications in human genetics and microbiome research.
The Axiom assay and workflow begins with purified genomic DNA. The first part of the assay and workflow is Target Preparation, which includes whole genome amplification on day one, followed by DNA fragmentation and overnight precipitation on day two. On day three the DNA is resuspended and prepared for hybridization on the array. Finally, washing, ligation, and staining occurs on the GeneTitan instrument followed by scanning of the plate. Target preparation aims to prepare the genomic targets of interest so that they can be successfully attached, or “hybridized”, to the synthesized probes on the microarray for accurate results. Following hybridization, array processing involves washing non-specific binding DNA and scanning the microarray plate to detect the fluorescence signal from the genomic targets of interest. Finally, genotypes are reported using Axiom Analysis Suite software.
Let’s dive deeper into each step:
Propel workflow: The above steps (excluding data analysis) have been optimized into a shortened two-day workflow, the Axiom Propel workflow, completing scanning of arrays by the end day 2. In addition, the Axiom Propel workflow has been optimized to include benchtop automation to increase the throughput, processing more plates in two days than the standard manual Axiom 2.0 assay.
For Research Use Only. Not for use in diagnostic procedures.